Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry

Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry

Abstract Background Until the approval of dabigatran etexilate, treatment choices for stroke prevention in patients with atrial fibrillation (AF) were vitamin K antagonists (VKAs) or antiplatelet drugs. This analysis explored whether availability of non‐vitamin K antagonist oral anticoagulants post‐...

Full description

Bibliographic Details
Main Authors: Changsheng Ma, Lionel Riou França, Shihai Lu, Hans‐Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Qiang Li, Miney Paquette, Christine Teutsch, Menno V. Huisman, Gregory Y. H. Lip, Kenneth J. Rothman, the GLORIA‐AF Investigators
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:Journal of Arrhythmia
Subjects:
anticoagulants
antiplatelet agents
atrial fibrillation
delivery of health care
stroke
Online Access:https://doi.org/10.1002/joa3.12321

Internet

https://doi.org/10.1002/joa3.12321

Similar Items